Journal of Clinical Oncology, Vol 16, 1954-1960, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B

TA Ahles, PM Silberfarb, J Herndon 2nd, LH Maurer, AB Kornblith, J Aisner, MC Perry, WL Eaton, LL Zacharski, MR Green and JC Holland
Dartmouth-Hitchcock Medical Center and the Norris Cotton Cancer Center, Lebanon, NH 03756, USA. tim.a.ahles@dartmouth.edu

PURPOSE: The current study assessed the psychologic and neuropsychologic functioning of patients with small-cell lung cancer who were randomized in a large clinical trial to receive intensive doxorubicin, cyclophosphamide, etoposide (ACE)/cisplatin, cyclophosphamide, etoposide (PCE) chemotherapy and radiation therapy (RT) to the primary tumor and prophylactic whole-brain irradiation with (regimen I) or without (regimen II) warfarin. PATIENTS AND METHODS: Patients' emotional states and cognitive functioning were assessed using the Profile of Mood States (POMS) and Trail Making B Test (Trails B), respectively. Two hundred ninety-five patients completed the POMS and Trails B at pretreatment, 224 patients after the completion of the ACE course of chemotherapy (week 9), and 177 patients after the completion of the PCE chemotherapy and RT (week 17). RESULTS: No differences on the POMS or Trails B measures were found between the two treatment arms as predicted, given that the only difference between the two treatment arms was the presence or absence of warfarin. Analysis of the POMS revealed that, overall, mean scores remained stable over the course of treatment; however, women showed a trend toward higher mean scores, which indicated a higher level of distress, compared with men at the pretreatment assessment. Examination of cognitive functioning, measured by the Trails B, revealed improved performance from baseline to post-ACE chemotherapy, which is consistent with a practice effect, but a significant worsening of Trails B scores post-RT compared with the pre-RT assessments, which is consistent with impaired cognitive functioning because of treatment (P < .0001). CONCLUSION: Emotional state, measured by the POMS, did not differ between the groups or change significantly over time in this study of small-cell lung cancer patients treated with a combination of chemotherapy and RT plus or minus warfarin. However, the pattern of relatively stable POMS scores and poorer Trails B performance post-RT suggested that this combination of chemotherapy and RT had a negative impact on cognitive functioning.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. S Gilchrist, M. L. Galantino, M. Wampler, V. G Marchese, G S. Morris, and K. K Ness A Framework for Assessment in Oncology Rehabilitation Physical Therapy, March 1, 2009; 89(3): 286 - 306. [Abstract] [Full Text] [PDF]

				M. Koithan, I. R. Bell, O. Caspi, L. Ferro, and V. Brown Patients' Experiences and Perceptions of a Consultative Model Integrative Medicine Clinic: A Qualitative Study Integr Cancer Ther, June 1, 2007; 6(2): 174 - 184. [Abstract] [PDF]

				E. E. Vokes, M. C. Perry, H. L. Kindler, and M. R. Green The cancer and leukemia group B respiratory committee. Clin. Cancer Res., June 1, 2006; 12(11): 3581s - 3588s. [Abstract] [Full Text] [PDF]

				L. H. Heflin, B. E. Meyerowitz, P. Hall, P. Lichtenstein, B. Johansson, N. L. Pedersen, and M. Gatz Cancer as a Risk Factor for Long-Term Cognitive Deficits and Dementia J Natl Cancer Inst, June 1, 2005; 97(11): 854 - 856. [Abstract] [Full Text] [PDF]

				E. A. Neuwelt, P. E. Guastadisegni, P. Varallyay, and N. D. Doolittle Imaging Changes and Cognitive Outcome in Primary CNS Lymphoma after Enhanced Chemotherapy Delivery AJNR Am. J. Neuroradiol., February 1, 2005; 26(2): 258 - 265. [Abstract] [Full Text] [PDF]

				C. L. Armstrong, J. V. Hunter, G. E. Ledakis, B. Cohen, E. M. Tallent, B. H. Goldstein, Z. Tochner, R. Lustig, K. D. Judy, A. Pruitt, et al. Late cognitive and radiographic changes related to radiotherapy: Initial prospective findings Neurology, July 9, 2002; 59(1): 40 - 48. [Abstract] [Full Text] [PDF]

				T. A. Ahles, A. J. Saykin, C. T. Furstenberg, B. Cole, L. A. Mott, K. Skalla, M. B. Whedon, S. Bivens, T. Mitchell, E. R. Greenberg, et al. Neuropsychologic Impact of Standard-Dose Systemic Chemotherapy in Long-Term Survivors of Breast Cancer and Lymphoma J. Clin. Oncol., January 15, 2002; 20(2): 485 - 493. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al. Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium Neuro-oncol, January 1, 2001; 3(1): 46 - 54. [Abstract] [PDF]

				A. T. Turrisi III Prophylactic Cranial Irradiation in Small-Cell Lung Cancer: Is It Still Controversial or Is It a No-Brainer? Oncologist, August 1, 2000; 5(4): 299 - 301. [Full Text]

				A. Auperin, R. Arriagada, J.-P. Pignon, C. Le Pechoux, A. Gregor, R. J. Stephens, P. E.G. Kristjansen, B. E. Johnson, H. Ueoka, H. Wagner, et al. Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission N. Engl. J. Med., August 12, 1999; 341(7): 476 - 484. [Abstract] [Full Text] [PDF]